vTv Therapeutics Expands Global Partnership with Newsoara for PDE4 Inhibitor HPP737 in $135 Million Deal
核心洞察
vTv Therapeutics has amended its license agreement with Newsoara Biopharma (搜索) to grant exclusive worldwide rights to develop and commercialize HPP737, a novel PDE4 (搜索) inhibitor for inflammation-mediated diseases.
The expanded partnership includes a $20 million upfront payment, with potential milestone payments totaling up to $115 million plus tiered royalties on net sales.
HPP737 demonstrates improved tolerability compared to existing PDE4 (搜索) inhibitors, showing little to no gastrointestinal distress in Phase 1 studies while maintaining potent anti-inflammatory activity.
vTv Therapeutics Inc. has significantly expanded its licensing partnership with Newsoara Biopharma (搜索) Co. Ltd., granting the Chinese biopharmaceutical company exclusive worldwide rights to develop and commercialize HPP737, a novel phosphodiesterase type 4 (PDE4 (搜索)) inhibitor. The amended agreement transforms what was previously a regional partnership into a global collaboration worth up to $135 million in total potential payments.
Strategic Partnership Details
Under the amended license agreement, vTv will receive an immediate upfront payment of $20 million upon execution. The deal structure includes additional milestone payments of up to approximately $50 million for development achievements and up to $65 million in sales milestones, plus tiered royalties based on net sales.
"We are pleased to expand our license with Newsoara to allow the further development and commercialization of HPP737 globally," said Paul Sekhri, Chairman, President and CEO of vTv Therapeutics. "The amendment strengthens our balance sheet with the upfront payment of $20 million and underscores the intrinsic value of our deep pipeline of differentiated therapeutic assets."
HPP737's Therapeutic Potential
HPP737 represents a potentially significant advancement in PDE4 (搜索) inhibitor therapy for inflammation-mediated diseases, particularly psoriasis (搜索). The compound has demonstrated potent inhibition of interleukin-23 (搜索) (IL-23) and tumor necrosis factor alpha (搜索) (TNF-α) production both in vitro and in vivo, along with therapeutic activity in several animal models of inflammation.
Critically, HPP737 appears to address a major limitation that has historically constrained the therapeutic potential of PDE4 (搜索) inhibitors. In Phase 1 studies, HPP737 was well tolerated with little or no gastrointestinal distress, potentially avoiding the dose-limiting adverse events including nausea and emesis that have limited other PDE4 inhibitors.
Mechanism and Clinical Advantages
PDE4 (搜索) inhibitors work by increasing intracellular cyclic adenosine monophosphate (AMP) levels, resulting in broad anti-inflammatory effects. However, the therapeutic potential of this drug class has historically been constrained by gastrointestinal side effects such as nausea, vomiting, and diarrhea.
Preclinical and clinical data suggest that HPP737 may circumvent these limitations while maintaining target engagement, as demonstrated in ex vivo studies. This improved tolerability profile could potentially expand the therapeutic applications for PDE4 (搜索) inhibition in inflammation-mediated diseases.
Global Development Strategy
Dr. Benny Li, Chief Executive Officer of Newsoara, emphasized the strategic value of the expanded collaboration: "We are pleased to expand our collaboration with vTv and secure global rights to HPP737, a highly differentiated oral PDE4 (搜索) inhibitor with the potential to address unmet needs in inflammation-mediated disease (搜索)."
Newsoara, established in 2018, focuses on three therapeutic areas: autoimmune diseases, oncology, and metabolic diseases. The company has been actively pursuing dual regulatory filings in China and the U.S. and currently has product candidates advancing in clinical trials across China, U.S., and Australia.
Portfolio Context
The HPP737 partnership complements vTv's primary focus on cadisegliatin, a liver-selective glucokinase (搜索) activator currently in Phase 3 trials for type 1 diabetes (搜索). Cadisegliatin has received Breakthrough Therapy designation from the FDA and represents a potential first-in-class oral adjunctive treatment to insulin.
Rich Nelson, Executive Vice President and Chief Business Officer of vTv Therapeutics, noted that "alliance management is a major strategic priority for vTv, and our strong relationship with Newsoara demonstrates this commitment and our mutual desire to advance new and innovative therapies for inflammation-mediated disease (搜索)."